Novo Nordisk EBITDA 2010-2024 | NVO
Novo Nordisk annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Novo Nordisk EBITDA for the quarter ending March 31, 2024 was $5.061B, a 31.41% increase year-over-year.
- Novo Nordisk EBITDA for the twelve months ending March 31, 2024 was $17.470B, a 41.46% increase year-over-year.
- Novo Nordisk 2023 annual EBITDA was $16.261B, a 39.75% increase from 2022.
- Novo Nordisk 2022 annual EBITDA was $11.635B, a 13.09% increase from 2021.
- Novo Nordisk 2021 annual EBITDA was $10.289B, a 12.16% increase from 2020.
Novo Nordisk Annual EBITDA
(Millions of US $) |
| 2023 |
$16,261 |
| 2022 |
$11,635 |
| 2021 |
$10,289 |
| 2020 |
$9,173 |
| 2019 |
$8,716 |
| 2018 |
$7,824 |
| 2017 |
$7,921 |
| 2016 |
$7,671 |
| 2015 |
$7,798 |
| 2014 |
$6,762 |
| 2013 |
$6,107 |
| 2012 |
$5,558 |
| 2011 |
$4,182 |
| 2010 |
$3,808 |
| 2009 |
$3,147 |
Novo Nordisk Quarterly EBITDA
(Millions of US $) |
| 2024-03-31 |
$5,061 |
| 2023-12-31 |
$4,300 |
| 2023-09-30 |
$4,298 |
| 2023-06-30 |
$3,812 |
| 2023-03-31 |
$3,851 |
| 2022-12-31 |
$2,666 |
| 2022-09-30 |
$2,982 |
| 2022-06-30 |
$2,851 |
| 2022-03-31 |
$3,136 |
| 2021-12-31 |
$2,421 |
| 2021-09-30 |
$2,623 |
| 2021-06-30 |
$2,593 |
| 2021-03-31 |
$2,652 |
| 2020-12-31 |
$2,024 |
| 2020-09-30 |
$2,366 |
| 2020-06-30 |
$2,215 |
| 2020-03-31 |
$2,568 |
| 2019-12-31 |
$1,963 |
| 2019-09-30 |
$2,234 |
| 2019-06-30 |
$2,191 |
| 2019-03-31 |
$2,328 |
| 2018-12-31 |
$1,616 |
| 2018-09-30 |
$1,959 |
| 2018-06-30 |
$2,073 |
| 2018-03-31 |
$2,176 |
| 2017-12-31 |
$1,744 |
| 2017-09-30 |
$2,030 |
| 2017-06-30 |
$2,111 |
| 2017-03-31 |
$2,036 |
| 2016-12-31 |
$1,778 |
| 2016-09-30 |
$1,971 |
| 2016-06-30 |
$2,010 |
| 2016-03-31 |
$1,913 |
| 2015-12-31 |
$1,771 |
| 2015-09-30 |
$1,882 |
| 2015-06-30 |
$1,944 |
| 2015-03-31 |
$2,201 |
| 2014-12-31 |
$1,544 |
| 2014-09-30 |
$1,525 |
| 2014-06-30 |
$1,605 |
| 2014-03-31 |
$1,476 |
| 2013-12-31 |
$1,346 |
| 2013-09-30 |
$1,419 |
| 2013-06-30 |
$1,504 |
| 2013-03-31 |
$1,339 |
| 2012-12-31 |
$1,323 |
| 2012-09-30 |
$1,322 |
| 2012-06-30 |
$1,322 |
| 2012-03-31 |
$1,126 |
| 2011-12-31 |
$675 |
| 2011-09-30 |
$1,110 |
| 2011-06-30 |
$1,162 |
| 2011-03-31 |
$1,105 |
| 2010-12-31 |
$1,037 |
| 2010-09-30 |
$1,184 |
| 2010-06-30 |
$1,017 |
| 2010-03-31 |
$789 |
| 2009-12-31 |
$1,009 |
| 2009-09-30 |
$806 |
| 2009-06-30 |
$749 |
| 2009-03-31 |
$687 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$591.861B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
